Resveratrol suppresses tumor progression via the regulation of indoleamine 2,3-dioxygenase

Biochemical and Biophysical Research Communications

Volumn 431, Issue 2, 2013, Pages 348-353

  Noh, Kyung Tae ^a   Chae, Seung Hoon ^a   Chun, Sung Hak ^c   Jung, In Duk ^a,b   Kang, Hyun Kyu ^a   Park, Yeong Min ^a,b  

^a Pusan National University School of Medicine   (South Korea)

^b Pusan National University   (South Korea)

^c Dongnam Institute of Radiological and Medical Science   (South Korea)

Author keywords

Anti tumor activity; Bone marrow derived dendritic cells; Indoleamine 2,3 dioxygenase; Resveratrol

Indexed keywords

GAMMA INTERFERON; INDOLEAMINE 2,3 DIOXYGENASE; JANUS KINASE; PROTEIN KINASE C DELTA; RESVERATROL; STAT1 PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW CELL; CANCER INHIBITION; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; ENZYME ACTIVITY; IMMUNOLOGICAL TOLERANCE; IMMUNOREGULATION; MALE; MOUSE; NONHUMAN; POLARIZATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; THYMOMA; TUMOR VOLUME;

ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; DENDRITIC CELLS; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; JANUS KINASES; MALE; MICE; MICE, INBRED C57BL; NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; STAT1 TRANSCRIPTION FACTOR; STILBENES; TUMOR ESCAPE;

MUS;

EID: 84873474982     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2012.12.093     Document Type: Article

References (31)

1. Banchereau J., Briere F., Caux C., Davoust J., Lebecque S., Liu Y.J., Pulendran B., Palucka K. Immunobiology of dendritic cells. Annu. Rev. Immunol. 2000, 18:767-811.
2. Mellor A.L., Munn D.H. IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat. Rev. Immunol. 2004, 4:762-774.
3. Lob S., Konigsrainer A., Rammensee H.G., Opelz G., Terness P. Inhibitors of indoleamine-2,3-dioxygenase for cancer therapy: can we see the wood for the trees?. Nat. Rev. Cancer 2009, 9:445-452.
4. Muller A.J., Prendergast G.C. Indoleamine 2,3-dioxygenase in immune suppression and cancer. Curr. Cancer Drug Targets 2007, 7:31-40.
5. Munn D.H., Mellor A.L. Indoleamine 2,3-dioxygenase and tumor-induced tolerance. J. Clin. Invest. 2007, 117:1147-1154.
6. Friberg M., Jennings R., Alsarraj M., Dessureault S., Cantor A., Extermann M., Mellor A.L., Munn D.H., Antonia S.J. Indoleamine 2,3-dioxygenase contributes to tumor cell evasion of T cell-mediated rejection. Int. J. Cancer 2002, 101:151-155.
7. Munn D.H., Sharma M.D., Hou D., Baban B., Lee J.R., Antonia S.J., Messina J.L., Chandler P., Koni P.A., Mellor A.L. Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. J. Clin. Invest. 2004, 114:280-290.
8. Uyttenhove C., Pilotte L., Theate I., Stroobant V., Colau D., Parmentier N., Boon T., Van den Eynde B.J. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat. Med. 2003, 9:1269-1274.
9. Zhang Y., Wang Y., Ogata M., Hashimoto S., Onai N., Matsushima K. Development of dendritic cells in vitro from murine fetal liver-derived lineage phenotype-negative c-kit(+) hematopoietic progenitor cells. Blood 2000, 95:138-146.
10. Hayashi T., Beck L., Rossetto C., Gong X., Takikawa O., Takabayashi K., Broide D.H., Carson D.A., Raz E. Inhibition of experimental asthma by indoleamine 2,3-dioxygenase. J. Clin. Invest. 2004, 114:270-279.
11. Takikawa O., Habara-Ohkubo A., Yoshida R. IFN-gamma is the inducer of indoleamine 2,3-dioxygenase in allografted tumor cells undergoing rejection. J. Immunol. 1990, 145:1246-1250.
12. Finbloom D.S., Larner A.C. Regulation of the Jak/STAT signalling pathway. Cell. Signal. 1995, 7:739-745.
13. Jeong Y.I., Kim S.W., Jung I.D., Lee J.S., Chang J.H., Lee C.M., Chun S.H., Yoon M.S., Kim G.T., Ryu S.W., Kim J.S., Shin Y.K., Lee W.S., Shin H.K., Lee J.D., Park Y.M. Curcumin suppresses the induction of indoleamine 2,3-dioxygenase by blocking the Janus-activated kinase-protein kinase Cdelta-STAT1 signaling pathway in interferon-gamma-stimulated murine dendritic cells. J. Biol. Chem. 2009, 284:3700-3708.
14. Baur J.A., Sinclair D.A. Therapeutic potential of resveratrol: the in vivo evidence. Nat. Rev. Drug Discovery 2006, 5:493-506.
15. Subramanian L., Youssef S., Bhattacharya S., Kenealey J., Polans A.S., van Ginkel P.R. Resveratrol: challenges in translation to the clinic - a critical discussion. Clin. Cancer Res. 2010, 16:5942-5948.
16. Kim G.Y., Cho H., Ahn S.C., Oh Y.H., Lee C.M., Park Y.M. Resveratrol inhibits phenotypic and functional maturation of murine bone marrow-derived dendritic cells. Int. Immunopharmacol. 2004, 4:245-253.
17. Noh K.T., Son K.H., Jung I.D., Kang H.K., Hwang S.A., Lee W.S., You J.C., Park Y.M. Protein kinase C delta (PKCdelta)-extracellular signal-regulated kinase 1/2 (ERK1/2) signaling cascade regulates glycogen synthase kinase-3 (GSK-3) inhibition-mediated interleukin-10 (IL-10) expression in lipopolysaccharide (LPS)-induced endotoxemia. J. Biol. Chem. 2012, 287:14226-14233.
18. Noh K.T., Park Y.M., Cho S.G., Choi E.J. GSK-3beta-induced ASK1 stabilization is crucial in LPS-induced endotoxin shock. Exp. Cell Res. 2011, 317:1663-1668.
19. Jung I.D., Jeong S.K., Lee C.M., Noh K.T., Heo D.R., Shin Y.K., Yun C.H., Koh W.J., Akira S., Whang J., Kim H.J., Park W.S., Shin S.J., Park Y.M. Enhanced efficacy of therapeutic cancer vaccines produced by co-treatment with mycobacterium tuberculosis heparin-binding hemagglutinin, a novel TLR4 agonist. Cancer Res. 2011, 71:2858-2870.
20. Jeong Y.I., Jung I.D., Lee J.S., Lee C.M., Lee J.D., Park Y.M. (-)-Epigallocatechin gallate suppresses indoleamine 2,3-dioxygenase expression in murine dendritic cells: evidences for the COX-2 and STAT1 as potential targets. Biochem. Biophys. Res. Commun. 2007, 354:1004-1009.
21. Kim S.I., Jeong Y.I., Jung I.D., Lee J.S., Lee C.M., Yoon M.S., Seong E.Y., Kim J.I., Lee J.D., Park Y.M. p-Coumaric acid inhibits indoleamine 2,3-dioxygenase expression in murine dendritic cells. Int. Immunopharmacol. 2007, 7:805-815.
22. Lee H.J., Jeong Y.I., Lee T.H., Jung I.D., Lee J.S., Lee C.M., Kim J.I., Joo H., Lee J.D., Park Y.M. Rosmarinic acid inhibits indoleamine 2,3-dioxygenase expression in murine dendritic cells. Biochem. Pharmacol. 2007, 73:1412-1421.
23. Hogquist K.A., Jameson S.C., Heath W.R., Howard J.L., Bevan M.J., Carbone F.R. T cell receptor antagonist peptides induce positive selection. Cell 1994, 76:17-27.
24. Yu Z., Theoret M.R., Touloukian C.E., Surman D.R., Garman S.C., Feigenbaum L., Baxter T.K., Baker B.M., Restifo N.P. Poor immunogenicity of a self/tumor antigen derives from peptide-MHC-I instability and is independent of tolerance. J. Clin. Invest. 2004, 114:551-559.
25. Mellor A. Indoleamine 2,3 dioxygenase and regulation of T cell immunity. Biochem. Biophys. Res. Commun. 2005, 338:20-24.
26. Boasso A., Herbeuval J.P., Hardy A.W., Winkler C., Shearer G.M. Regulation of indoleamine 2,3-dioxygenase and tryptophanyl-tRNA-synthetase by CTLA-4-Fc in human CD4+ T cells. Blood 2005, 105:1574-1581.
27. Prendergast G.C. Immune escape as a fundamental trait of cancer: focus on IDO. Oncogene 2008, 27:3889-3900.
28. Dorrie J., Gerauer H., Wachter Y., Zunino S.J. Resveratrol induces extensive apoptosis by depolarizing mitochondrial membranes and activating caspase-9 in acute lymphoblastic leukemia cells. Cancer Res. 2001, 61:4731-4739.
29. Fukui M., Yamabe N., Zhu B.T. Resveratrol attenuates the anticancer efficacy of paclitaxel in human breast cancer cells in vitro and in vivo. Eur. J. Cancer 2010, 46:1882-1891.
30. Sun W., Wang W., Kim J., Keng P., Yang S., Zhang H., Liu C., Okunieff P., Zhang L. Anti-cancer effect of resveratrol is associated with induction of apoptosis via a mitochondrial pathway alignment. Adv. Exp. Med. Biol. 2008, 614:179-186.
31. Aggarwal B.B., Bhardwaj A., Aggarwal R.S., Seeram N.P., Shishodia S., Takada Y. Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies. Anticancer Res. 2004, 24:2783-2840.